Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications

Hepatits C virus (HCV) rates have lowered due to direct‐acting antiviral treatment. Nonalcoholic steatohepatitis (NASH)/nonalcoholic fatty liver disease (NAFLD) is rising with no available therapy. We employed text‐mining to analyze trends in HCV and NAFLD research from the past two decades.

[1]  A. Sanyal,et al.  An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  M. Andreoni,et al.  Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  A. Sanyal,et al.  Therapeutic pipeline in nonalcoholic steatohepatitis , 2021, Nature Reviews Gastroenterology & Hepatology.

[4]  W. Chan,et al.  Nonalcoholic Fatty Liver Disease: A Global Perspective. , 2021, Clinical therapeutics.

[5]  P. Kwo,et al.  Current and future strategies for the treatment of chronic hepatitis C , 2020, Clinical and molecular hepatology.

[6]  S. Abd-Elsalam,et al.  Treatment of hepatitis C Cirrhotic patients with directly acting antivirals: A multicenter study. , 2020, Infectious disorders drug targets.

[7]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[8]  V. Wong,et al.  Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016 , 2020, Journal of internal medicine.

[9]  Lai Wei,et al.  How would China achieve WHO’s target of eliminating HCV by 2030? , 2019, Expert review of anti-infective therapy.

[10]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[11]  E. Gorospe,et al.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. , 2017, Gastroenterology.

[12]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[13]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[14]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[15]  Cuihua Lu,et al.  Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta‐analysis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[17]  A. Tavakoli,et al.  Evaluation of urinary interleukin-8 levels in patients with spinal cord injury. , 2014, Recent patents on anti-infective drug discovery.

[18]  N. Einollahi,et al.  Survey of serum procalcitonin in cirrhotic patients. , 2013, Acta medica Iranica.

[19]  Ding-Shinn Chen,et al.  High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. , 2012, Gastroenterology.

[20]  A. Galluzzo,et al.  Visceral adiposity index is associated with significant fibrosis in patients with non‐alcoholic fatty liver disease , 2012, Alimentary pharmacology & therapeutics.